RxDoctor Payments Data

Abdelhakim Kasmia, MD

Neurology · Fairhope, ALNPI 1821033127

Payments from drug & device makers

$12,303in general payments, 2019–2025

Across 649 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Medtronic$952
  • Lilly USA, LLC$811
  • Pfizer$676
  • Novartis$670
  • Teva Pharmaceuticals USA, Inc.$601
  • plus $6K from 40 others

What the payments were for

  • Speaking & faculty fees$150%
  • Travel & lodging$8017%
  • Food & beverage$11,37792%
  • Education$1101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,303 in reported general payments places this provider in the 60th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$138,818
Medicare patients
369
Services billed
6,171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5028$381,741
BetaseronInterferon Beta-1b11$102,665
Gamunex-CImmune Globul G/Gly/Iga Avg 4618$83,072
AptiomEslicarbazepine Acetate35$69,087
QuliptaAtogepant31$38,047
BotoxOnabotulinumtoxina23$29,410
Nurtec OdtRimegepant Sulfate24$28,914
Emgality PenGalcanezumab-Gnlm34$23,367
RytaryCarbidopa/Levodopa12$20,153
Rivastigmine15$6,394
Entacapone23$5,000
Lacosamide29$4,913
Memantine Hcl184$4,523
Carbidopa-LevodopaCarbidopa/Levodopa82$3,869
Levetiracetam129$3,612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$63$381,74128 claims
Grifols USA, LLCGamunex-C$67$83,07218 claims
AbbVieQulipta, Botox$2,381$67,45754 claims
PfizerNurtec Odt, Dilantin$676$30,46235 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$147$23,24740 claims
Upsher-smith Laboratories LLCTopiramate$48$1,547120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 255 neurology providers in Alabama.

Other neurology in Fairhope

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →